Background on ImmunOs´multi-targeting approach for remodeling the tumor microenvironment

The Company’s multi-targeting approach is remodeling the tumor microenvironment (TME) – a key prerequisite for immunotherapy to work. This remodeling of the TME occurs in different ways: 

  • First, ImmunOs´ products stimulate the innate immune system directly by activating M1-type macrophages and suppressing M2-type macrophages. Shifting from the M2 to M1-type TME is vital as the M1-type facilitates a robust immune response to tumors. 
  • Second, ImmunOs´ products block immuno-suppressive myeloid-derived suppressor cells (MDSCs), allowing the expansion of killer CD8+ T cells, which can directly destroy cancer. In addition to remodeling the TME, ImmunOs ´products directly stimulate NK-cells which can have a strong anti-tumor effect.

As a result, the Company´s molecules are suited as a monotherapy or in combination therapy to make the environment more amenable to immunotherapy and have demonstrated strong anti-tumor responses in multiple cancer indications in combination with checkpoint inhibitors such as CTLA-4, PD-1, PD-L1, CD47, SIRPα and agonist antibodies such as 4-1BB.

ImmunOs Therapeutics believes that its novel family class of immunomodulators, which stimulate the immune system and increase the efficacy of both checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47, SIRPα) and co-stimulatory agonists (e.g. 4-1BB) in combination therapies will spearhead the next wave of personalized treatments to support patients with a diverse set of cancer indications.